Mammoth Biosciences IPO

Mammoth Biosciences, based in Brisbane, Calif., was founded in 2017 by Trevor Martin, the company’s CEO, and Janice Chen, Lucas Harrington, and Jennifer Doudna. The company, which was last valued at $1.08 billion in September 2021, is developing novel CRISPR systems to cure and detect diseases. CRISPR is a tool that can allow researchers to alter DNA sequences and modify gene function.

In November, the company was named to Fast Company’s 2022 list of the “Next Big Things in Tech.” In September 2021, the company raised $150 million in Series D financing from a group of investors including Redmile Group, Foresite Capital, Greenspring Associates and Senator Investment Group.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for Mammoth Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Mammoth Biosciences's ticker symbol?

Mammoth Biosciences does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

What is Mammoth Biosciences's stock price?

The stock price for Mammoth Biosciences will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Who are Mammoth Biosciences's major investors?

Mayfield Fund
Foresite Capital
Decheng Capital
NFX
Redmile Group

Mammoth Biosciences Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
9/9/2021 Series D and D-1 $1.08B $XXX.XX $XXX.XX
11/4/2020 Series C and C-1 $278.7MM $XXX.XX $XXX.XX
1/30/2020 Series B and B-1 $144.13MM $XXX.XX $XXX.XX
8/8/2018 Series A $36.19MM $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Mammoth Biosciences

Forge green plus iconForge green minus icon

What is Mammoth Biosciences funding to date?

Mammoth Biosciences has raised $257.38MM with the following series:
$36.19MM for Series A, $144.13MM for Series B and B-1, $278.7MM for Series C and C-1, $1.08B for Series D and D-1, $36.19MM for Series A, $144.13MM for Series B and B-1, $278.7MM for Series C and C-1, $1.08B for Series D and D-1.
Forge green plus iconForge green minus icon

When was Mammoth Biosciences founded?

Mammoth Biosciences was founded in 2017.
Forge green plus iconForge green minus icon

Can you invest in Mammoth Biosciences?

Mammoth Biosciences is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Mammoth Biosciences share pre-IPO?

If you own Mammoth Biosciences pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Mammoth Biosciences a publicly traded company?

Mammoth Biosciences is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Other companies like Mammoth Biosciences in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
 
 
Sector
Last Round Est. Valuation
$298.33MM